2022 International Congress Archives - Page 134 of 153

Gait abnormalities relate to increased extracellular water in the substantia nigra in Parkinson’s disease patients

M. Bange, G. Gonzalez-Escamilla, N. Lang, A. Radetz, H. Ding, D. Herz, W. Schöllhorn, M. Muthuraman, S. Groppa (Mainz, Germany)
Gait Analysis in Normal Pressure Hydrocephalus: a Meta-Analysis

M. Passaretti, A. Maranzano, B. Bluett, A. Fasano (Rome, Italy)
GAIT ANALYSIS IN PARKINSONIAN SUBJECTS WITH PISA SYNDROME SUBJECTED TO TREATMENT WITH BOTULINUM TOXIN

R. Marvulli, G. Ianieri, A. Zonno, G. Mintrone, G. Farì, L. Rizzo, M. Ranieri, M. Megna (Bari, Italy)
Gait analysis using Wearable Sensors: different gait metrics can differentiate Parkinson’s Disease Patients from Healthy Controls and Parkinson’s Disease patients in different medication status

R. Barbosa, M. Medonça, R. Oliveira, M. Santos, A. Abreu, P. Bastos, P. Pita-Lobo, A. Valadas, L. Correia-Guedes, J. Ferreira, M. Rosa, R. Matias, M. Coelho (Lisbon, Portugal)
Gait and Balance Characteristics in Atypical Parkinsonian Syndromes

V. Sidoroff, C. Raccagni, K. Seppi, H. Gassner, J. Winkler, N. Hergenröder-Lenzner, N. Roth, B. Eskofier, S. Buechner, D. Benninger, K. Aminian, G. Wenning (Innsbruck, Austria)
Gait ataxia and Autonomic dysfunction as early signs of Creutzfeldt-Jakob Disease: A Case Report

S. Zaheer, E. Urrea-Mendoza, V. Veerappan (Greenville, USA)
Gait Characteristics from Daily Life Increase Ability to Predict Future Falls in People with Parkinson’s Disease

V. Shah, J. Mcnames, G. Harker, P. Carlson-Kuhta, J. Nutt, M. El Gohary, K. Sowalsky,, M. Mancini, F. Horak (Portland, USA)
Gait declines faster over time in people with Parkinson’s disease converting to a freezing of gait phenotype

T. Virmani, A. Glover, L. Pillai (Little Rock, USA)
Gait under unsupervised, but not supervised conditions, differentiates between Parkinson disease with and without fatigue

A. Rizzardi, A. Pilotto, C. Hansen, C. Zatti, G. Bonzi, R. Romijnders, W. Maetzler, A. Padovani (Brescia, Italy)
GDNF Gene Therapy for Parkinson’s Disease (PD): Preliminary Safety and Clinical Findings from a Phase Ib Study

A. van Laar, C. Christine, A. Merola, N. Phielipp, B. Elder, P. Larson, N. Stoicea, W. San Sebastian, M. Fiandaca, A. Kells, K. Bankiewicz (Research Triangle Park, USA)
Gender Identity and Treatment Response in Patients with Functional Tic-Like Behavior

S. Kola, D. Larson (Chicago, USA)
Gender-related sexual dysfunction in Parkinson disease: Clinical data of a hospital cohort in Tunisia

L. Ali, H. Jamoussi, N. Ben Ali, S. Fray, M. Ben Mahmoud, M. Fredj (Tunis, Tunisia)
Gene and variant curation of Parkinson’s disease genes by an authoritative expert panel

J. Beck, K. Lohmann, L. Lange, A. Naito, A. Kumeh, C. Thaxton, M. Weaver, S. Strom, R. Alcalay (New York, USA)
Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia

M. Baile, D. Schecter, A. Miller, T. Galas, N. Scherer, R. Chen, N. Ruiz, D. Bettoun (Philadelphia, USA)
Genetic contribution to domain specific cognitive decline

V. Livneh, N. Omer, N. Giladi, T. Gurevich, A. Bar-Shira, M. Gana-Weisz, O. Goldstein, J. Shirvan, J. Cedarbaum, A. Orr-Urtreger, R. Alcalay, A. Mirelman, A. Thaler (Tel Aviv, Israel)
Genetic correlation and potential causal relationship between inflammatory bowel disease and Parkinson’s disease

S. Grover, E. Wacker, A. Kumar-Sreelatha, A. Elbaz, R. Krüger, T. Gasser, D. Ellinghaus, M. Sharma (Tuebingen, Germany)
Genetic determinants of early motor progression in Parkinson’s cohorts

A. Martinez-Carrasco, M. Lawton, R. Real, M. Tan, C. Carroll, JC. Corvol, D. Grosset, M. Hu, J. Hardy, N. Williams, Y. Ben-Shlomo, M. Shoai, H. Morris (London, United Kingdom)
Genetic landscape of dystonia in Asian Indian patients

R. Rajan, A. Saini, R. Mewara, B. Verma, D. Radhakrishnan, E. Arunmozhimaran, A. Gupta, V. Vishnu, M. Singh, R. Bhatia, R. Mir, I. Singh, F. Mohammed, B. Binukumar, V. Scaria, A. Srivastava, P. Srivastava (New Delhi, India)
Genetic stratification of motor and quality of life outcomes in Parkinson’s disease in the EARLYSTIM study

D. Weiss, Z. Landoulsi, P. May, M. Sharma, M. Schüpbach, H. You, JC. Corvol, S. Paschen, AK. Helmers, M. Barbe, G. Fink, A. Kühn, C. Brefel-Courbon, L. Wojtecki, P. Damier, V. Fraix, JL. Houeto, J. Regis, F. Sixel-Döring, M. Pinsker, S. Thobois, A. Gharabaghi, V. Stoker, L. Timmermann, A. Schnitzler, P. Krack, M. Vidailhet, G. Deuschl, R. Krüger (Tübingen, Germany)
Genetics Of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) : Genetics of Juvenile, Young and Early Onset Parkinson’s Disease

P. Kukkle, V. Goyal, T. Geetha, R. Menon, R. Kandadai, U. Mahadevia, H. Kumar, R. Borgohain, A. Mukherjee, P. Wadia, R. Yadav, S. Desai, N. Kumar, S. Nair, S. Murugan, A. Biswas, P. Pal, M. Oliver, S. Sundaram, M. Deshmukh, A. Bassi, C. Sandeep, N. Mandloi, A. Kayalvizhi, U. Muthane, S. Das, S. Seshagiri, R. Gupta, V. Ramprasad (Bangalore, India)
Genome-wide association study of Aβ, t-tau and p-tau in CSF in Parkinson’s disease

H. Iwaki (Bethesda, USA)
Genome-wide meta-analysis of Parkinson’s disease identifies a novel chromosomal 22 locus: findings from the COURAGE-PD consortium

S. Grover, A. Kumar-Sreelatha, Z. Landoulsi, P. May, D. Bobbili, C. Domenighetti, C. Schulte, PE. Sugier, A. Elbaz, R. Krüger, T. Gasser, M. Sharma (Tuebingen, Germany)
Geographic and Financial Trends in the Utilization of Deep Brain Stimulation in the Medicare Population from 2013-2019

T. Gossard, A. Khurana, J. Chan, S. Aslam (Phoenix, USA)
Gerstmann-Sträussler-Scheinker disease presenting as dystonia

J. Kim (Busan, Republic of Korea)
Gerstmann-Straussler-Scheinker Syndrome Manifesting Levodopa-Responsive Parkinsonism, Levodopa-Induced Dyskinesia, and Abnormal DaT-SPECT

S. Aradi (Tampa, USA)
Giant symptomatic capillary telangiectasia: uncommon cause of cerebellar ataxia

A. Fernández Revuelta, V. Gómez Mayordomo, M. Hernández Holgado, M. Fernández García, A. Baltasar Corral, E. López Valdés, R. García-Ramos (Madrid, Spain)
GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms

O. de Fabregues, A. Pascual-Rodríguez, M. de Lucca, M. Sellés, F. Palau, G. Fernández, J. Hoenicka (Barcelona, Spain)
Glial neurotrophic factor as an early diagnostic marker in Parkinson’s disease

M. Matmurodov, A. Abduqodirov, L. Khalimova, B. Muminov (Tashkent, Uzbekistan)
Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)
GLUT1 Deficiency Syndrome with Novel mutation responsive to GPi DBS

C. Torres Vásquez, C. Zepeda Salazar, M. Rodriguez Violante, G. Cervantes Arriaga, D. Tristan, V. Cerino, T. Ortegano, A. Abundes Corona (Ciudad de mexico, Mexico)
GNAO1 related disorders: a clinical, genetic, and therapeutic update

M. Novelli, S. Galosi, G. Zorzi, T. Granata, F. Nardecchia, M. Di Rocco, S. Martinelli, N. Nardocci, V. Leuzzi (Rome, Italy)
Goals for Improvement in Essential Tremor Patients Following Focused Ultrasound VIM Thalamotomy

L. O'Brien, K. Lyons, V. Sharma, R. Pahwa (Kansas City, USA)
Gold and silver nanoparticle-based Localized Surface Plasmon Resonance Sensor (LSPR) for the detection of histidine as a potential biomarker in Parkinson’s Disease.

E. Robles, C. Acevedo-Castillo, D. Martínez-Ramírez (Monterrey, Mexico)
GP2: Growing a research community in the Parkinson’s disease genetics field through training and networking

S. Dey, A. Noyce, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, J. Callanan, A. Martinez-Carrasco, S. Bandres-Ciga, G. Genetics Program (London, United Kingdom)
GPi-DBS induced brain metabolic activation in cervical dystonia

EA. Honkanen, J. Korpela, E. Pekkonen, J. Aaltonen, M. Koivu, O. Eskola, H. Eldebakey, J. Volkmann, V. Kaasinen, MM. Reich, J. Joutsa (Turku, Finland)
Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes

M. Banwinkler, V. Dzialas, M. Hoenig, T. van Eimeren (Cologne, Germany)
Gray matter volumetry, cortical thickness and cognitive performance in treated Parkinson’s disease with REM sleep behavior disorder symptomatology

J. Oltra, A. Campabadal, C. Uribe, J. Pardo, MJ. Marti, Y. Compta, F. Valldeoriola, N. Bargallo, A. Iranzo, C. Junque, B. Segura (Barcelona, Spain)
Grey and white matter brain structural alterations in patients with Essential Tremor plus dystonic soft signs

D. Brinker, O. Granert, I. Tödt, R. Wolke, G. Deuschl, J. Becktepe (Kiel, Germany)
GRIN2D is a cause of autosomal dominant form of Parkinson’s disease

A. Kishore, M. Sturm, J. Shin, S. Grover, F. Raimondi, C. Blauwendraat, S. Robert, G. Sarma, N. Casadei, P. Lichtner, A. Kumar-Sreelatha, J. Winkelmann, R. Krüger, A. Singleton, T. Gasser, P. Seth, J. Roeper, O. Riess, M. Sharma (Kochi, India)
GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase show evidence of pharmacological efficacy in conduritol β-epoxide (CBE) models of Parkinson’s disease

B. Guzman, N. Perez, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, A. Henriques, L. Rouviere, R. Maj (Lugano, Switzerland)
Gut dysbiosis in patients with dementia with Lewy bodies

H. Nishiwaki, M. Ito, T. Hamaguchi, K. Kashihara, T. Maeda, Y. Tsuboi, M. Katsuno, M. Hirayama, K. Ohno (Nagoya, Japan)